Nephrosis: Clinical Trials

10 trials for Nephrosis, newest first

ClinicalTrials Daily  ·  Areas  ·  Conditions  ·  Drugs  ·  Sponsors  ·  

10 completed. 10 Phase 1, 2 Phase 2.

By phase and status

PhaseTrialsStatus
Phase 110Completed 10
Phase 22Completed 2

Follow Nephrosis: new trials by email Literature Review of Nephrosis trials Research Report on Nephrosis

Trials (filtered) newest first · largest first

All 10 trials

Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.

TrialPhaseStatusSponsorEnrollmentStartUpdated
Efficacy And Safety Of Azithromycin To Achieve Remissionin In Children With Steroid Sensitive Nephrotic Syndrome
Azithromycin and steroids, steroids - Nephrotic Syndrome
Phase 1CompletedUniversity of Child Health Sciences and Children's Hospital, Lahore1602025-03-082026-01-06
Safety and Pharmacokinetic Study of Subcutaneous ALXN1720 in Participants With Proteinuria
ALXN1720 - Proteinuria
Phase 1CompletedAlexion Pharmaceuticals, Inc.132022-06-292023-06-29
A Prospective Multi-dose Study of Apixaban in Subjects With Nephrotic Syndrome
Apixaban 5 MG - Nephrotic Syndrome, Membranous Nephropathy
Phase 1CompletedUniversity of North Carolina, Chapel Hill222021-04-142023-09-26
Causes and Prevention of Thromboembolic Disease in Nephrotic Syndrome
Dalteparin, Apixaban - Nephrotic Syndrome, Thromboembolic Disease
Phase 1 / Phase 2CompletedUniversity of Aarhus572021-03-252025-04-11
FIH Ph 1 Study of TRPC5 Channel Inhibitor GFB-887 in Healthy Subjects
GFB-887, Placebo - Healthy Volunteers
Phase 1CompletedGoldfinch Bio, Inc.702019-05-292020-06-02
Pharmacokinetics of Apixaban in Nephrotic Syndrome
apixaban - Nephrotic Syndrome, Proteinuria
Phase 1CompletedUniversity of North Carolina, Chapel Hill212017-04-302019-07-24
A Phase 1 Multiple Ascending Dose Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of ManNAc in Subjects With Primary Podocyte Diseases
N-acetyl D-mannosamine - Kidney Disease
Phase 1CompletedNational Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)102016-07-072023-02-24
Lipid Lowering Agents to Limit Lipid Oxidation and Activation of Clotting System in Nephrotic Syndrome
Pravastatin - Nephrotic Syndrome, Hyperlipidemia
Phase 1CompletedUniversity of North Carolina, Chapel Hill72012-05-012018-08-29
IL-2 for Multi Drug Resistant Nephrotic Syndrome
Proleukin® - Nephrotic Syndrome
Phase 1 / Phase 2CompletedIstituto Giannina Gaslini52012-02-012015-05-28
Pharmacokinetics Following Single-dose of Valsartan in Japanese Pediatric Patients
Valsartan (VAL489) - Hypertension, Chronic Kidney Disease
Phase 1CompletedNovartis Pharmaceuticals122011-08-012020-12-21

Narrower conditions

Nephrotic Syndrome (9)  ·  Proteinuria (5)  ·  Diabetic Nephropathies (2)  ·  Glomerulonephritis (2)  ·  Glomerulonephritis, Membranous (2)  ·  Glomerulosclerosis, Focal Segmental (2)  ·  Kidney Diseases (2)  ·  Renal Insufficiency, Chronic (2)  ·  Diabetes Complications (1)  ·  Endocrine System Diseases (1)  ·  Glomerulonephritis, IGA (1)  ·  Glomerulonephritis, Membranoproliferative (1)  ·  Hematuria, Benign Familial (1)  ·  Hyperlipidemias (1)  ·  Hypertension (1)

Broader conditions

Female Urogenital Diseases (10)  ·  Female Urogenital Diseases and Pregnancy Complications (10)  ·  Male Urogenital Diseases (10)  ·  Urogenital Diseases (10)  ·  Urologic Diseases (9)  ·  Kidney Diseases (8)  ·  Pathological Conditions, Signs and Symptoms (6)  ·  Signs and Symptoms (5)  ·  Urination Disorders (5)  ·  Urological Manifestations (5)  ·  Autoimmune Diseases (3)  ·  Immune System Diseases (3)  ·  Nephritis (3)  ·  Cardiovascular Diseases (2)

Interventions

apixaban (3)  ·  Azithromycin (1)  ·  Dalteparin (1)  ·  Interleukin-2 (1)  ·  N-acetylmannosamine (1)  ·  Pravastatin (1)  ·  Steroids (1)  ·  Valsartan (1)  ·  aldesleukin (1)

Sponsors

University of North Carolina, Chapel Hill (3)  ·  Alexion Pharmaceuticals, Inc. (1)  ·  Goldfinch Bio, Inc. (1)  ·  Istituto Giannina Gaslini (1)  ·  National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) (1)  ·  Novartis Pharmaceuticals (1)  ·  University of Aarhus (1)  ·  University of Child Health Sciences and Children's Hospital, Lahore (1)

Countries

United States (5)  ·  Denmark (1)  ·  Italy (1)  ·  Japan (1)  ·  Pakistan (1)  ·  South Korea (1)

Top investigators

Daniel Crona, PharmD, PhD (2)  ·  Dr. Ummara Subhani, MD (1)  ·  Gian Marco Ghiggeri, MD (1)  ·  Jeanelle Kam, MD (1)  ·  Jeffrey B Kopp, M.D. (1)  ·  Sarah Kelddal, MD (1)  ·  Vimal Derebail, MD (1)  ·  Vimal Derebail, MD, MPH (1)

Results publications

PMID 26413873, PMID 40478760, PMID 41333097, PMID 41630898, PMID 41805697

NIH funding

U54DK083912 (1)